urea has been researched along with Kidney, Polycystic in 26 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Methods The clinical data of ESRD patient whose primary diagnosis was PKD in Peking Union Medical College Hospital were retrospectively collected from January 1993 to December 2015." | 1.46 | Effectiveness of Peritoneal Dialysis in Treating Adult End Stage Renal Disease Patients with Polycystic Kidney Disease. ( Chen, LM; Li, XM; Li, Y; Liu, BY; Ma, Y; Wang, HY; Xia, JH; Yang, W; Zhou, ZJ, 2017) |
| "Thus, the polycystic kidney produces FGF23 but is resistant to its action." | 1.40 | Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease. ( Biber, J; Edenhofer, I; Jaeger, P; Mohebbi, N; Pavik, I; Petzold, K; Saleh, L; Segerer, S; Serra, AL; Spichtig, D; Stange, G; Wagner, CA; Zhang, H, 2014) |
| "Polycystic kidney disease is the most common potentially lethal single- gene inherited disease in man." | 1.29 | Amelioration of polycystic kidney disease by modification of dietary protein intake in the rat. ( Ogborn, MR; Sareen, S, 1995) |
| "Pyelonephritis was a very common complication, but was present only in patients from groups 2 and 3, in whom a lumen was present in the draining ureter, and not in patients from group 1 in whom the ureter was atretic or absent, and the kidney not functioning." | 1.25 | Renal dysplasia. I. A clinico-pathological study of 76 cases. ( Risdon, RA, 1971) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (61.54) | 18.7374 |
| 1990's | 3 (11.54) | 18.2507 |
| 2000's | 3 (11.54) | 29.6817 |
| 2010's | 4 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ma, Y | 1 |
| Wang, HY | 1 |
| Zhou, ZJ | 1 |
| Li, Y | 1 |
| Yang, W | 1 |
| Liu, BY | 1 |
| Xia, JH | 1 |
| Li, XM | 1 |
| Chen, LM | 1 |
| Spichtig, D | 1 |
| Zhang, H | 1 |
| Mohebbi, N | 1 |
| Pavik, I | 1 |
| Petzold, K | 1 |
| Stange, G | 1 |
| Saleh, L | 1 |
| Edenhofer, I | 1 |
| Segerer, S | 1 |
| Biber, J | 1 |
| Jaeger, P | 1 |
| Serra, AL | 1 |
| Wagner, CA | 1 |
| Grotemeyer, D | 1 |
| Voiculescu, A | 1 |
| Iskandar, F | 1 |
| Voshege, M | 1 |
| Blondin, D | 1 |
| Balzer, KM | 1 |
| Rump, LC | 1 |
| Sandmann, W | 1 |
| Bhimani, JP | 1 |
| Ouseph, R | 1 |
| Ward, RA | 1 |
| Wiedmeyer, CE | 1 |
| Royal, AB | 1 |
| SALISBURY, PF | 1 |
| POMERANZ, AA | 1 |
| DUNEA, G | 1 |
| KOLFF, WJ | 1 |
| Nosková-Lyerová, L | 1 |
| Viklický, O | 1 |
| Schück, O | 1 |
| Ward, JN | 1 |
| Draper, JW | 1 |
| Lavengood, RW | 1 |
| Mowat, AP | 1 |
| Barsotti, G | 1 |
| Cupisti, A | 1 |
| Moriconi, L | 1 |
| Cozza, V | 1 |
| Falbo, E | 1 |
| Gattai, V | 1 |
| Pozzolini, L | 1 |
| Meola, M | 1 |
| Ogborn, MR | 1 |
| Sareen, S | 1 |
| Riedel, E | 1 |
| Nündel, M | 1 |
| Hampl, H | 1 |
| Jayapalan, S | 1 |
| Saboorian, MH | 1 |
| Edmunds, JW | 1 |
| Aukema, HM | 1 |
| Selgas, R | 1 |
| Muñoz, J | 1 |
| Miranda, B | 1 |
| Ramos, P | 1 |
| Caparros, G | 1 |
| Revuelta, KL | 1 |
| Gonzalez, A | 1 |
| Gallar, P | 1 |
| Sanchez Sicilia, L | 1 |
| Wright, FW | 1 |
| Ledingham, JG | 1 |
| Dunnill, MS | 1 |
| Grieve, NW | 1 |
| Pohl, JE | 1 |
| Thurston, H | 1 |
| Swales, JD | 1 |
| Milman, N | 1 |
| Mazo, EB | 1 |
| Saxton, HM | 1 |
| Cameron, JS | 1 |
| Chantler, C | 1 |
| Ogg, CS | 1 |
| Caissel, J | 1 |
| Hall, GH | 1 |
| Holman, HM | 1 |
| Webster, AD | 1 |
| Risdon, RA | 1 |
| Berlyne, GM | 1 |
| Gaan, D | 1 |
| Ginks, WR | 1 |
| Blagg, CR | 1 |
| Kemble, F | 1 |
| Taverner, D | 1 |
| Gardner, KD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect Of Dialysate Flow Rate On Mass Transfer Coefficient - Area (KoA) In Dialyzers With Different Membrane Packing Densities[NCT00636077] | 12 participants (Actual) | Interventional | 2008-02-29 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00636077)
Timeframe: During the third treatment with each dialyzer (one time during each trial period week)
| Intervention | KoA for b2-microglobulin (mL/min) (Mean) | ||
|---|---|---|---|
| 350 mL/min Dialysate Flow Rate | 500 mL/min Dialysate Flow Rate | 800 mL/min Dialysate Flow Rate | |
| F160NR | 27 | 28 | 31 |
| F200NR | 27 | 25 | 21 |
| HD-C4 Big | 65 | 62 | 64 |
| HD-C4 Small | 61 | 57 | 56 |
(NCT00636077)
Timeframe: During the third treatment with each dialyzer (one time during each trial period week)
| Intervention | KoA for Phosphorus (mL/min) (Mean) | ||
|---|---|---|---|
| 350 mL/min Dialysate Flow Rate | 500 mL/min Dialysate Flow Rate | 800 mL/min Dialysate Flow Rate | |
| F160NR | 434 | 450 | 458 |
| F200NR | 504 | 491 | 560 |
| HD-C4 Big | 434 | 435 | 520 |
| HD-C4 Small | 334 | 422 | 415 |
KoA is a constant that describes the efficiency of a dialyzer in removing urea. KoA is determined by surface area of the membrane, the thickness of the membrane and pore size. (NCT00636077)
Timeframe: During the third treatment with each dialyzer (one time during each trial period week)
| Intervention | KoA for urea (mL/min) (Mean) | ||
|---|---|---|---|
| 350 mL/min Dialysate Flow Rate | 500 mL/min Dialysate Flow Rate | 800 mL/min Dialysate Flow Rate | |
| F160NR | 770 | 738 | 809 |
| F200NR | 798 | 890 | 817 |
| HD-C4 Big | 844 | 898 | 922 |
| HD-C4 Small | 763 | 748 | 761 |
(NCT00636077)
Timeframe: During the third treatment with each dialyzer (one time during each trial period week)
| Intervention | whole blood clearance B2-microglobulin (Mean) | ||
|---|---|---|---|
| 350 mL/min Dialysate Flow Rate | 500 mL/min Dialysate Flow Rate | 800 mL/min Dialysate Flow Rate | |
| F160NR | 87 | 86 | 78 |
| F200NR | 72 | 65 | 75 |
| HD-C4 Big | 106 | 129 | 118 |
| HD-C4 Small | 119 | 118 | 121 |
(NCT00636077)
Timeframe: During the third treatment with each dialyzer (one time during each trial period week)
| Intervention | whole blood phosphorus clearance mL/min (Mean) | ||
|---|---|---|---|
| 350 mL/min Dialysate Flow Rate | 500 mL/min Dialysate Flow Rate | 800 mL/min Dialysate Flow Rate | |
| F160NR | 247 | 260 | 272 |
| F200NR | 249 | 265 | 281 |
| HD-C4 Big | 255 | 269 | 286 |
| HD-C4 Small | 252 | 261 | 273 |
(NCT00636077)
Timeframe: During the third treatment with each dialyzer (one time during each trial period week)
| Intervention | Whole blood urea clearance (mL/min) (Mean) | ||
|---|---|---|---|
| 350 mL/min Dialysate Flow Rate | 500 mL/min Dialysate Flow Rate | 800 mL/min Dialysate Flow Rate | |
| F160NR | 271 | 293 | 313 |
| F200NR | 274 | 313 | 327 |
| HD-C4 Big | 279 | 315 | 340 |
| HD-C4 Small | 270 | 295 | 320 |
1 review available for urea and Kidney, Polycystic
| Article | Year |
|---|---|
Hepatic Disorders.
Topics: Adolescent; Adult; alpha 1-Antitrypsin Deficiency; Amino Acid Metabolism, Inborn Errors; Ammonia; Ch | 1982 |
1 trial available for urea and Kidney, Polycystic
| Article | Year |
|---|---|
alpha-Ketoglutarate application in hemodialysis patients improves amino acid metabolism.
Topics: Adult; Aged; Amino Acids; Calcium Carbonate; Chromatography, High Pressure Liquid; Female; Glomerulo | 1996 |
24 other studies available for urea and Kidney, Polycystic
| Article | Year |
|---|---|
Effectiveness of Peritoneal Dialysis in Treating Adult End Stage Renal Disease Patients with Polycystic Kidney Disease.
Topics: Adult; Creatinine; Female; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Male; Middle | 2017 |
Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease.
Topics: Adaptor Proteins, Signal Transducing; Animals; Biomarkers; Calcitriol; Calcium; Creatinine; Disease | 2014 |
Renal cysts in living donor kidney transplantation: long-term follow-up in 25 patients.
Topics: Adult; Aged; Creatinine; Female; Follow-Up Studies; Functional Laterality; Humans; Kidney Transplant | 2009 |
Effect of increasing dialysate flow rate on diffusive mass transfer of urea, phosphate and beta2-microglobulin during clinical haemodialysis.
Topics: beta 2-Microglobulin; Cross-Over Studies; Dialysis Solutions; Female; Glomerulonephritis; Humans; Hy | 2010 |
Urinary biomarkers for monitoring disease progression in the Han:SPRD-cy rat model of autosomal-dominant polycystic kidney disease.
Topics: Acetylglucosaminidase; Albuminuria; Animals; Biomarkers; Collagen Type IV; Creatinine; Disease Progr | 2010 |
UREMIC TOXICITY CORRELATED WITH UNIDENTIFIED ANIONS.
Topics: Anions; Blood Chemical Analysis; Creatine; Creatinine; Edema; Glomerulonephritis; Ileostomy; Kidney; | 1963 |
CLINICAL EXPERIENCE WITH THE YATZIDIS CHARCOAL ARTIFICIAL KIDNEY.
Topics: Blood Chemical Analysis; Blood Glucose; Blood Platelets; Calcium; Charcoal; Creatine; Creatinine; Gl | 1965 |
[Hypernatraemia, increased protein intake and progression of renal insufficiency in a patient with polycystic renal degeneration].
Topics: Cerebral Hemorrhage; Dietary Proteins; Disease Progression; Diuresis; Humans; Hypernatremia; Male; M | 2001 |
A clinical review of polycystic kidney disease in 53 patients.
Topics: Adolescent; Adult; Aged; Angiography; Child; Child, Preschool; Diagnosis, Differential; Female; Hema | 1967 |
Effects of reduced protein intake in rats with congenital polycystic kidney without renal failure.
Topics: Animals; Body Weight; Creatinine; Diet, Protein-Restricted; Disease Progression; Male; Polycystic Ki | 1995 |
Amelioration of polycystic kidney disease by modification of dietary protein intake in the rat.
Topics: Animals; Creatinine; Diet, Protein-Restricted; Dietary Proteins; Male; Polycystic Kidney Diseases; R | 1995 |
High dietary fat intake increases renal cyst disease progression in Han:SPRD-cy rats.
Topics: Animals; Body Weight; Dietary Fats; Disease Models, Animal; Estradiol; Female; Male; Organ Size; Pol | 2000 |
Induced changes of the peritoneal diffusion capacity by smoking, intraabdominal hypertension and omentectomy.
Topics: Abdomen; Adult; Aged; Creatinine; Diabetic Nephropathies; Diffusion; Humans; Kidney Failure, Chronic | 1989 |
Polycystic kidneys, renal hamartomas, their variants and complications.
Topics: Acute Kidney Injury; Adult; Angiography; Blood Pressure; Creatinine; Diagnosis, Differential; Female | 1974 |
Hypertension with renal impairment: influence of intensive therapy.
Topics: Adolescent; Adult; Chronic Disease; Creatinine; Diazoxide; Female; Glomerulonephritis; Humans; Hyper | 1974 |
Blood transfusion requirements before and after bilateral nephrectomy in patients undergoing chronic hemodialysis.
Topics: Adult; Antibodies; Blood Pressure; Blood Transfusion; Chronic Disease; Creatinine; Female; Glomerulo | 1974 |
The role of arterial pressure dynamics in the diagnosis of renal graft rejection crisis.
Topics: Adult; Arteries; Blood Pressure; Body Temperature; Cadaver; Creatinine; Diuresis; Glomerulonephritis | 1972 |
Renal puncture in infancy.
Topics: Female; Humans; Infant; Infant, Newborn; Kidney Diseases, Cystic; Male; Methods; Pneumothorax; Polyc | 1973 |
[Renal failure in polycystic kidney (surgical treatment)].
Topics: Adult; Creatinine; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Male; Methods; Polyc | 1971 |
Anticoagulation by ancrod for haemodialysis.
Topics: Adult; Anticoagulants; Cellophane; Chronic Disease; Fibrin; Fibrinogen; Heparin; Humans; Leukocytes; | 1970 |
Renal dysplasia. I. A clinico-pathological study of 76 cases.
Topics: Cartilage; Child; Child, Preschool; Chronic Disease; Epithelium; Female; Humans; Hydronephrosis; Inf | 1971 |
Dietary treatment of chronic renal failure.
Topics: Acidosis; Creatinine; Diet Therapy; Dietary Proteins; Glomerular Filtration Rate; Glomerulonephritis | 1968 |
Nerve conduction velocity in relationship to the severity of renal disease.
Topics: Adult; Amyloidosis; Creatinine; Female; Glomerulonephritis; Humans; Hypertension, Renal; Kidney Calc | 1968 |
Composition of fluid in twelve cysts of a polycystic kidney.
Topics: Adult; Amino Acids; Ammonia; Body Fluids; Calcium; Chromatography; Creatinine; Glucose; Humans; Hydr | 1969 |